Lapatinib selectively inhibits HER2-amplified gastric cancer cells (Wainberg et al., 2010), and Rapamycin and Sunitinib target angiogenesis, significantly inhibiting tumor angiogenesis in vivo (Lang et al., 2007; Lyros et al., 2010). This evidence concerns the gene ERBB2 and gastric cancer.